AMP-activated Protein Kinase as a Drug Target in Chronic Kidney Disease.
Curr Drug Targets
; 19(6): 709-720, 2018.
Article
em En
| MEDLINE
| ID: mdl-28571536
ABSTRACT
BACKGROUND:
Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMPactivated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD.OBJECTIVE:
The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Insuficiência Renal Crônica
/
Proteínas Quinases Ativadas por AMP
/
Terapia de Alvo Molecular
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Drug Targets
Ano de publicação:
2018
Tipo de documento:
Article